Dexchlorpheniramine

Last updated
Dexchlorpheniramine
Dexchlorpheniramine.svg
Clinical data
Trade names Chlor-trimeton, Polaramine
AHFS/Drugs.com Monograph
MedlinePlus a682543
Routes of
administration 		Oral, Intravenous
ATC code
Legal status
Legal status
  • AU: S3 (Pharmacist only)
Pharmacokinetic data
Elimination half-life 21 to 27 hours
Identifiers
  • (3S)-3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-3-ylpropan-1-amine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.042.779 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C16H19ClN2
Molar mass 274.79 g·mol−1
3D model (JSmol)
  • Clc1ccc(cc1)[C@@H](c2ncccc2)CCN(C)C
  • InChI=1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1 Yes check.svgY
  • Key:SOYKEARSMXGVTM-HNNXBMFYSA-N Yes check.svgY
   (verify)

Dexchlorpheniramine (trade name Polaramine) is an antihistamine with anticholinergic properties used to treat allergic conditions such as hay fever or urticaria. [1] [2] It is the pharmacologically active dextrorotatory isomer of chlorpheniramine.

Contents

It came into medical use in 1959 and was patented in 1962. [3]

Pharmacology

Dexchlorpheniramine is an antihistamine, or an antagonist of the histamine H1 receptor. A study found that dexchlorpheniramine had a Ki value of 20 to 30 μM for the muscarinic acetylcholine receptors using rat brain tissue. [4]

References

  1. ↑ Theunissen EL, Vermeeren A, Ramaekers JG (January 2006). "Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance". British Journal of Clinical Pharmacology. 61 (1): 79–86. doi:10.1111/j.1365-2125.2005.02524.x. PMC   1884990 . PMID   16390354.
  2. ↑ Ortíz San Román L, Sanavia Morán E, Campos Domínguez M, Peinador García MM (December 2013). "[Anticholinergic syndrome due to dexchlorpheniramine as a cause of urinary retention]". Anales de Pediatria. 79 (6): 400–401. doi:10.1016/j.anpedi.2013.02.014. PMID   23680058.
  3. ↑ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 547. ISBN   9783527607495.
  4. ↑ Yamamura HI, Snyder SH (May 1974). "Muscarinic cholinergic binding in rat brain". Proceedings of the National Academy of Sciences of the United States of America. 71 (5): 1725–1729. Bibcode:1974PNAS...71.1725Y. doi: 10.1073/pnas.71.5.1725 . PMC   388311 . PMID   4151898.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.